Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated
A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in...
670 Views
Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs
On January 3, 2019, Bristol Myers Squibb Co (BMY US) and Celgene Corp (CELG US) announced a definitive agreement for BMY to acquire Celgene in a...
836 Views
Taisho Frontrunner to Acquire BMS’s French OTC Business
Event – Bristol Myers Squibb Co (BMY US)'s French OTC business UPSA has been on the block since June 2018. According to a December 17, 2018...
583 Views
Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement
Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...
406 Views
Innovent Biologics IPO First-Day: Take Money off the Table
Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...
514 Views